安派科(AnPac Bio)在美获得重要新型微型医疗设备专利 (英文)

自媒体 自媒体


AnPac Bio Granted Important Novel Micro Medical Device Patent in the United States


NEWS PROVIDED BY AnPac Bio-Medical Science Co., Ltd. 

SAN JOSE, Calif., March 24, 2020 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the allowance by  the United States Patent and Trademark Office on March 5, 2020, of a US patent application claiming an integrated and decomposable micro apparatus that can be used for site-specific delivery of a drug, a medical kit, a micro disease detection system, or even an auto-navigation system for in vivo applications.

Cancer Differentiation Analysis Technology

"As a leader in using biophysical properties to scan and detect changes in blood and other liquid samples, we wanted to make sure that our technology and patents also include our devices to have the option of being in vivo so that we can constantly test and detect changes in the in the human body," said Dr. Chris Yu, CEO and Chairman of AnPac Bio. "Due to our fundamental pending and issued patents in the US and many other jurisdictions covering the entire spectrum of disease detection, as well as micro surgical operations and drug release responses, intellectual properties of biophysical measurements with multi-functional micro- medical devices will have significant value in the future."

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection with two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, AnPac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. AnPac Bio's CDA technology has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information, please visit: https://www.Anpacbio.com.

For investor and media inquiries, please contact:

Phil Case, Marketing and Investor Relations
Email: phil_case@AnPacbio.com

Investor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Email: tina.xiao@ascent-ir.com   

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "target," "aim," "predict," "outlook," "seek," "goal" "objective," "assume," "contemplate," "continue," "positioned," "forecast," "likely," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; and our relationship with our major business partners and customers. Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

转自prnewswire.com 起原 SOURCE AnPac Bio-Medical Science Co., Ltd.

本文由「华尔街俱乐部」介绍,敬请关注公家号: wallstreetclub





  1. NO.1 AI技术下的娱乐圈女星全都.avi了

    这是娱乐圈行动派——去酱 的第32篇《我去》 今天,我看了好几个女星的小黄片(封面) 这两天,有手艺人把杨幂的五官换到了《射雕英雄传》的黄蓉脸上(原朱茵饰)↓你们看了没?

  2. NO.2 剑三怎么抓马地点(剑三重制版马驹刷新点)

    龙子和麟驹天天的刷新纪律是 早上7点到11点是一轮 正午11点到15点是一轮 下昼15点到19点是一轮 晚上19点到23点是一轮 凌晨23点到03点是一轮 凌晨03点到07点是一轮 每轮刷新6只龙子麟驹各

  3. NO.3 明星大侦探甄完美谁扮演的 宋妍霏大跳热舞惊艳众人


  4. NO.4 李嘉诚纪念亡妻的庄月明楼,是风水宝地还是锁魂阴棺?

    对了!蜜桃哥哥看见很多小可爱们问,我新增的长文系列菜单栏在哪里,来来来,蜜桃哥哥手把手教你们回溯以往的长文系列。 首先进入 “圈内密探” 的公众号主页,然后

  5. NO.5 《火焰之纹章 风花雪月》三大势力学生能力介绍,你选好了吗?

    距离《火焰之纹章 风花雪月》发售还有一周的时间,然则网上的一些介入过测试的媒体与视频博主已经起头狂吹不止,被他们喻为史上最强的火纹续作。 首个媒体评分由Fami通给出,获

  6. NO.6 暗黑破坏神3武僧攻略有哪些(2019暗黑3武僧升级加点技能分析)

    今天小编就带人人从根源下手,具体认识一下这套BD的输出机制与弄法。 乌莲娜套简称捂脸,是使用爆裂掌作为首要危险的弄法,爆炸结果酷炫,群伤优势显着,在能打的动的前提下清

  7. NO.7 2019年暗黑3什么职业单刷最好最快(暗黑3十大单人冲榜主流玩法


  8. NO.8 超合金魂盖塔皇帝终于来了!盖塔战舰简直帅爆!

    关注wx公众号:涛哥测评,掌握玩具最新资讯 近日,万代超合金魂正式公布了超合金魂盖塔皇帝的先行官图,分体形态下的盖塔战舰也太帅了吧,这让我对合体的造型充满了